ADMS News Alert Adamas Pharmaceuticals Inc. (ADMS) 16.10 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Adamas Pharmaceuticals Inc. (ADMS) 16.10 $ADMS

Taser and Walgreen are big market movers
AP - Wed Dec 24, 12:37PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
RIG: 18.77 (-0.37), BRP: 24.01 (+1.15), ADMS: 16.10 (+1.45), TASR: 26.86 (+0.84), WAG: 76.67 (+0.16)

Market News: Adamas Pharmaceuticals, Virgin America, CalAmp
at The Street - Wed Dec 24, 12:21PM CST
The stock markets in the United States continue to advance with that Russell 2000 close to reaching a record level today. Sign up for our free daily newsletter Yesterday, the Dow Jones Industrial Aver...
VA: 41.00 (+5.19), CAMP: 17.74 (-1.98), ADMS: 16.10 (+1.45)

Premarket Gainers / Losers as of 9:10 ET
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 8:12AM CST

NVGS: 20.00 (+2.10), ACHN: 13.06 (+1.22), ADMS: 16.10 (+1.45), DGLY: 15.62 (+0.82)

FDA clears Adamas Alzheimer's drug
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 7:52AM CST

ACT: 254.20 (-1.68), ADMS: 16.10 (+1.45)

Actavis and Adamas Announce FDA Approval of Namzaric(TM), a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride
PR Newswire - Wed Dec 24, 7:00AM CST
Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor. Namzaric was approved for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride.
ACT: 254.20 (-1.68), ADMS: 16.10 (+1.45)

First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST

IPXL: 31.32 (+0.26), ADMS: 16.10 (+1.45), TEVA: 57.09 (+0.33), ACOR: 39.14 (+0.74), PRTA: 20.14 (+1.41), NDRM: 5.90 (-0.19)

Adamas Pharmaceuticals wins six additional US patents for amantadine HCl
M2 - Wed Dec 03, 8:26AM CST
Pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) reported on Tuesday that it has received six additional patents in the US, bringing the total number of issued patents for amantadine-based controlled-release products to nine, with 12 more applications pending.
ADMS: 16.10 (+1.45)

Adamas Pharmaceuticals Issued Six Additional U.S. Patents
GlobeNewswire - Tue Dec 02, 8:01AM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) announced the issuance of six additional US patents (US 8,889,740; US 8,895,614; US 8,895,615; US 8,895,616; US 8,895,617 and US 8,895,618), bringing the total number of issued patents for amantadine-based controlled-release products owned by Adamas to nine, with 12 more applications pending. The newly issued patents include both composition of matter claims and claims covering methods for treatment of neurological diseases, including Parkinson's disease, related to the pharmacokinetic profile of amantadine HCl.
ADMS: 16.10 (+1.45)

Adamas Pharmaceuticals to Present at Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 18, 11:00AM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the 26 Annual Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014 at 3:30 PM Eastern Time.
ADMS: 16.10 (+1.45)

Adamas Pharmaceuticals to Present at 2014 Credit Suisse Healthcare Conference
GlobeNewswire - Wed Nov 05, 3:02PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the 2014 Credit Suisse Healthcare Conference in Phoenix, AZ on Tuesday, November 11, 2014 at 7:30 AM Mountain Time.
ADMS: 16.10 (+1.45)

Adamas Pharma misses by $0.13, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:44PM CST

ADMS: 16.10 (+1.45)

Adamas Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 3:03PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported a net loss attributable to common stockholders of $9.6 million, or $0.57 per share, for the quarter ended September 30, 2014. In the same period last year, the company reported a net loss attributable to common stockholders of $3.4 million, or $0.36 per share. Adamas ended the current quarter with $137.5 million in cash and cash equivalents, compared to $85.6 million at December 31, 2013.
ADMS: 16.10 (+1.45)

Adamas Pharmaceuticals Expands Its Phase 3 Program With ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Patients With Parkinson's Disease
GlobeNewswire - Tue Oct 28, 3:01PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it has initiated an additional Phase 3 safety and efficacy study evaluating ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. ADS-5102, an investigational agent, is a high dose, controlled-release version of amantadine HCl administered once daily at bedtime.
ADMS: 16.10 (+1.45)

Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT

BIIB: 340.89 (+5.13), MNOV: 3.04 (unch), CHTP: 6.52 (-0.03), ADMS: 16.10 (+1.45), ACOR: 39.14 (+0.74), BCLI: 3.85 (+0.22), BSX: 13.13 (+0.07), IPXL: 31.32 (+0.26), AVNR: 16.91 (+0.01), ACAD: 30.95 (+0.78), CVTS: (), MRK: 57.46 (+0.25), TEVA: 57.09 (+0.33), PRTA: 20.14 (+1.41), PRAN: 1.74 (-0.02), FOLD: 7.94 (+0.06), CUR: 2.70 (+0.07)

OTC Daily Alert Stock Watch - Adamas Pharmaceuticals, Inc., (NASDAQ: ADMS)
WorldStockWire - Sat Oct 18, 11:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ADMS: 16.10 (+1.45)

5 Big-Volume Stocks to Trade for Big Breakouts
at The Street - Thu Oct 02, 8:20AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
MDVN: 99.23 (+1.23), RCAP: 11.23 (+0.26), ADMS: 16.10 (+1.45), TRGP: 104.31 (+1.60), NRG: 27.74 (+0.60)

Adamas Pharmaceuticals Announces Management Changes
GlobeNewswire - Wed Aug 13, 3:05PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced changes to its management team.
ADMS: 16.10 (+1.45)

Adamas Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 3:44PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported net income attributable to common stockholders of $16.4 million, or $0.88 per share on a fully diluted basis, for the quarter ended June 30, 2014. In the same period last year, the company reported a net loss attributable to common stockholders of $3.4 million, or $0.35 per share on a fully diluted basis. The difference between the two periods was primarily the result of the recognition of revenue associated with the collaboration with Forest Laboratories, Inc. (acquired by Actavis plc in July 2014).
ADMS: 16.10 (+1.45), FRX: 99.00 (-0.77)

Adamas Pharmaceuticals receives US Patent No. 8,796,337 for ADS-5102 and amantadine product candidates
M2 - Wed Aug 06, 5:48AM CDT
Specialist pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) reported on Tuesday the receipt of the US Patent No. 8,796,337, entitled "Composition and Method For Treating Neurological Disease" from the US Patent and Trademark Office (USPTO).
ADMS: 16.10 (+1.45)

United States Patent Issued to Adamas Pharmaceuticals
GlobeNewswire - Tue Aug 05, 3:08PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS), today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,796,337, entitled "Composition and Method For Treating Neurological Disease." The claims of this patent are directed towards methods for treating human subjects with amantadine therapy, including Adamas' lead product candidate ADS-5102 and similar amantadine-based products.
ADMS: 16.10 (+1.45)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Human Frontier Mission Puts AI Research on Display

Updated Category News Views 45

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 182

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 121

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 105

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 104

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 140

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 98

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 97

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

Stellantis NV: Short Interest Shift Sparks Investor Sentiment Questions

Updated Category News Views 299

Stellantis NV's (NYSE:STLA) short interest saw a notable drop of 13.81% since its last report, now standing at 44.96 million shares sold short, or about 1.56% of all tradable shares. Sounds like good news, right? But hang on—this isn't just a free pass to pop the champagne. When we talk short interest, we're peeling back layers on market sentiment that can turn on a...

Continue Reading
Minerals Technologies Showcases Innovative PFAS Solutions at Symposium

Updated Category News Views 185

Minerals Technologies to Present at Gabelli Funds PFAS Symposium Minerals Technologies Inc. (MTI) is thrilled to announce its participation in the upcoming PFAS Symposium hosted by Gabelli Funds. This notable event is set to take place in New York City, bringing together key figures in the industry to discuss significant advancements and novel strategies for tackling...

Continue Reading
Morning Market Insights for Key Stocks: A Daily Review

Updated Category News Views 338

Daily Market Insights: Leading Stocks to Watch Good morning, traders. Today’s notes zero in on SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA—names that tend to steer the broader tape. Our read on price comes from a blend of key levels shaped by price action, trading volume, and options flow. We refresh these levels daily and share them with Market Clubhouse...

Continue Reading
Exploring the Evolving Landscape of Electric Vehicles in the U.S.

Updated Category News Views 224

The Current State of Electric Vehicles in the U.S. The electric vehicle (EV) landscape in the U.S. is experiencing transformative changes. As the country marks significant milestones in EV deployment, there are noteworthy gaps in infrastructure and consumer attitudes that need addressing. The third annual HERE-SBD EV Index reveals how far the U.S. has come, yet highlights...

Continue Reading
eBay's Legal Victory: Dismissal of Harmful Product Claims

Updated Category News Views 173

eBay's legal drama hit the news when the U.S. government slammed them with a lawsuit accusing the online giant of violating the Clean Air Act back in 2024. The crux? Selling products that supposedly helped folks skirt around those pesky auto pollution controls. You know how it is—desks buzzing about regulatory risks, and traders getting twitchy over such moves. The...

Continue Reading